Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Cathy Kelly
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.
Guidelines for US health care providers could help prevent shortages as demand for possible treatments surge, groups say. Stakeholders also argue “Buy America” executive order would hamper drug access.
What's in – and what fell out of – the massive US stimulus package.
US House leadership's COVID-19 aid package focuses on cost sharing relief for patients to ensure access to treatments and vaccines for the virus. The Senate's legislative proposal tried to provide Medicare reimbursement incentives to providers to facilitate uptake, but some of those provisions were later dropped.
Provisions adapted from DISARM Act would carve out antimicrobials from hospital bundled payments and allow reimbursement equal to 100% of a drug’s average sales price.
Legislation allows sponsors to request HCPCS code even before US FDA approval, but would extend the sequester until 2030 to pay for the temporary increase in payments for Part B drugs.